These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1442 related items for PubMed ID: 14633722

  • 1. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K, Kontani K, Ozaki Y, Sawai S, Tezuka N, Nagata T, Fujino S, Itoh Y, Taguchi O, Koide Y, Asai T, Ohkubo I, Ogasawara K.
    Cancer Res; 2003 Nov 15; 63(22):7920-5. PubMed ID: 14633722
    [Abstract] [Full Text] [Related]

  • 2. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
    Maecker HT, Umetsu DT, DeKruyff RH, Levy S.
    J Immunol; 1998 Dec 15; 161(12):6532-6. PubMed ID: 9862678
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
    Park JY, Jin DH, Lee CM, Jang MJ, Lee SY, Shin HS, Chung YH, Kim KY, Kim SS, Lee WB, Shin YK, Lee WJ, Park YM, Kim D.
    J Immunother; 2010 Jun 15; 33(5):510-22. PubMed ID: 20463596
    [Abstract] [Full Text] [Related]

  • 5. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
    Ye Z, Ahmed KA, Hao S, Zhang X, Xie Y, Munegowda MA, Meng Q, Chibbar R, Xiang J.
    Autoimmunity; 2008 Nov 15; 41(7):501-11. PubMed ID: 18855194
    [Abstract] [Full Text] [Related]

  • 6. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
    Rowe HM, Lopes L, Ikeda Y, Bailey R, Barde I, Zenke M, Chain BM, Collins MK.
    Mol Ther; 2006 Feb 15; 13(2):310-9. PubMed ID: 16275163
    [Abstract] [Full Text] [Related]

  • 7. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S, Yuan J, Xiang J.
    J Leukoc Biol; 2007 Oct 15; 82(4):829-38. PubMed ID: 17626150
    [Abstract] [Full Text] [Related]

  • 8. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F.
    Cancer Immunol Immunother; 2004 Nov 15; 53(11):963-77. PubMed ID: 15146294
    [Abstract] [Full Text] [Related]

  • 9. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
    Kikuchi T, Uehara S, Ariga H, Tokunaga T, Kariyone A, Tamura T, Takatsu K.
    Immunology; 2006 Jan 15; 117(1):47-58. PubMed ID: 16423040
    [Abstract] [Full Text] [Related]

  • 10. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K, Wakita D, Narita Y, Zhang Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.
    Cancer Res; 2006 Feb 01; 66(3):1809-17. PubMed ID: 16452242
    [Abstract] [Full Text] [Related]

  • 11. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N, Brown JM, Demcheva M, Kelley JR, Lockett MA, Vournakis J, Cole DJ.
    Clin Cancer Res; 1999 May 01; 5(5):1173-82. PubMed ID: 10353754
    [Abstract] [Full Text] [Related]

  • 12. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K.
    J Immunol; 1999 Jan 01; 162(1):144-51. PubMed ID: 9886380
    [Abstract] [Full Text] [Related]

  • 13. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H, Okamoto T, Kanzaki M, Inozume T, Shibagaki N, Shimada S.
    Br J Dermatol; 2010 Jan 01; 162(1):29-41. PubMed ID: 19863514
    [Abstract] [Full Text] [Related]

  • 14. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA, Orsini C, Lindinger P, Thalhamer J, Abrams SI.
    Cell Immunol; 2000 Nov 01; 205(2):73-83. PubMed ID: 11104579
    [Abstract] [Full Text] [Related]

  • 15. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H, Li F, Gordon JR, Xiang J.
    Cancer Res; 2002 Apr 01; 62(7):2043-51. PubMed ID: 11929823
    [Abstract] [Full Text] [Related]

  • 16. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
    Zeng G.
    J Immunother; 2001 Apr 01; 24(3):195-204. PubMed ID: 11394496
    [Abstract] [Full Text] [Related]

  • 17. Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines.
    Dobaño C, Rogers WO, Gowda K, Doolan DL.
    Immunol Lett; 2007 Aug 15; 111(2):92-102. PubMed ID: 17604849
    [Abstract] [Full Text] [Related]

  • 18. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y, Mayumi H, Eto M, Nomoto K.
    J Immunol; 1990 Mar 15; 144(6):2425-35. PubMed ID: 1968930
    [Abstract] [Full Text] [Related]

  • 19. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.
    Clin Immunol; 2009 Nov 15; 133(2):184-97. PubMed ID: 19664962
    [Abstract] [Full Text] [Related]

  • 20. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI, Khleif SN, Bergmann-Leitner ES, Kantor JA, Chung Y, Hamilton JM, Schlom J.
    Cell Immunol; 1997 Dec 15; 182(2):137-51. PubMed ID: 9514698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.